Table 1.
Methotrexate monitoring guidelines used by dermatologists for psoriasis and by rheumatologists for psoriatic arthritis.
Fig 1.
Selection, inclusion and exclusion of study population from the hospital database: Patients seen at least once between 2006 and 2015.
Table 2.
Characteristics of patients with psoriasis or psoriatic arthritis.
Table 3.
Laboratory monitoring during first treatment course with MTX.
Fig 2.
Continuation of methotrexate in first observed treatment course for psoriasis by dermatologists and psoriatic arthritis treated by rheumatologists (log-rank test: p<0.001).
Table 4.
Reasons for withdrawal from the first course of MTX in patients with psoriasis or psoriatic arthritis.
Table 5.
Serious adverse events (SAE) in patients while using methotrexate (first and later courses).